Nasdaq ikna.

May 18, 2023 · IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ... Ikena Oncology, Inc. (NASDAQ:IKNA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The business earned $3.75 million during the quarter, compared to analysts' expectations of $2.92 million.7 août 2023 ... ... Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr ...Common Stock, $0.001 par value per share IKNA The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule . 12b-2. of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒That’s why at the end of this article we will examine companies such as Talos Energy, Inc. (NYSE:TALO), Radius Health Inc (NASDAQ:RDUS), and Ikena Oncology, Inc. (NASDAQ:IKNA) to gather more ...

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology Inc (NASDAQ: IKNA)’s stock price has gone decline by -62.23 in comparison to its previous close of 4.13, however, the company has experienced a -61.58% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology,

Webull offers Ikena Oncology Inc stock information, including NASDAQ: IKNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKNA stock news, and many more online research tools to help you make informed decisions. Nov 7, 2023 · BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...May 18, 2023 · IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ... Pair this with the current uncertainty in markets and it would not be too surprising to see investors considering pharmaceutical stocks today. Take Ikena Oncology ( NASDAQ: IKNA) for instance. All ...Investing.com - Ikena Oncology (NASDAQ: IKNA) divulgou lucro por ação (LPA) de $-0,40 no terceiro trimestre, $0,03 acima da estimativa dos analistas de $-0,43.A receita trimestral foi de $1,19M, contra o consenso de mercado de $2,84M. As ações da Ikena Oncology fecharam em $1,33. Elas caíram -69,07% nos últimos 3 meses e caíram …Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics. His prior investments include Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL, acquired by Merck), Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL), Horizon …

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three ...

May 15, 2023 · Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...

Nov 26, 2023 · American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […] Jun 28, 2021 · Every investor in Ikena Oncology, Inc. (NASDAQ:IKNA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies ... 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: IKNA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week. Volatility Over Time: IKNA's weekly volatility has increased from 16% to 23% over the past year.May 15, 2023 · Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ... Dec 11, 2021 · About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ... BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...

IKEA retailer Ingka Group is spending 3 billion euros ($3.2 billion) through 2023 on new and existing stores, much of it to modify its trademark out-of-town outlets so they can double up as e ...(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares climbed 128.8% to settle at $9.06 on Tuesday.KludeIn I Acquisition Corp. Class A Common Stock (INKA) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

IKNA technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Ikena Oncology, Inc. is based on the most popular …Dow jones falls over 200 points on thursday; the nasdaq and s&p 500 also trade lower. Krispy kreme reports downbeat results for third quarter; energy shares rise by 0.3%. …

Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79%. (Simply Wall St.) Mar-17-22 07:00AM. Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (GlobeNewswire) +23.30%. Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...Ikena Oncology (NASDAQ:IKNA) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better business?We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, …Ikena Oncology Stock Earnings. The value each IKNA share was expected to gain vs. the value that each IKNA share actually gained. Ikena Oncology ( IKNA) reported Q3 2023 earnings per share (EPS) of -$0.40, beating estimates of -$0.43 by 7.29%. In the same quarter last year, Ikena Oncology 's earnings per share (EPS) was -$0.48.BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79%. (Simply Wall St.) Mar-17-22 07:00AM. Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (GlobeNewswire) +23.30%.

Ikena Oncology Inc (NASDAQ: IKNA) nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway. The ...

As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.

BOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena™”, “Company”), a targeted oncology company forging new territory in patient-directed cancer ...Find the latest news headlines from Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...Ikena Oncology (NASDAQ:IKNA) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM.. Here's what investors need to know about the announcement. Earnings. Ikena Oncology beat ...10 août 2023 ... (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ...As of September 30, 2021, the Company had cash and cash equivalents totaling $245.9 million, which will fund operations through 2023. Net cash used in operations was $18.0 million for the third ...The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...

Oct 26, 2022 · BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR ...BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Instagram:https://instagram. trvn stock forecastbest option trading strategyarm stock price today per sharerobinhood margin interest rate KludeIn I Acquisition Corp. Class A Common Stock (INKA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. who is todd snydercigna dental discount May-16-23 08:29AM · Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts. (Simply Wall St.) -12.00% ; 09: ... tal nyse Financial Results for the Quarter Ended March 31, 2023. As of March 31, 2023, Ikena had $137.8 million in cash, cash equivalents and marketable securities, which does not include proceeds from the ...Gainers Celcuity Inc. (NASDAQ:CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreemen...